Cancer has recently been identified as the leading cause of mortality worldwide. Several conventional treatments and cytotoxic immunotherapies have been developed and made available to the market. Considering the complex behavior of tumors and the involvement of numerous genetic and cellular factors involved in tumorigenesis and metastasis, there is a need to develop a promising immunotherapy that targets tumors at both the cellular and genetic levels. Chimeric antigen receptor (CAR) T cell therapy has emerged as a novel therapeutic T cell engineering practice, in which T cells derived from patient blood are engineered in vitro to express artificial receptors targeted to a specific tumor antigen. These directly identify the tumor antigen without the involvement of the major histocompatibility complex. The use of this therapy in the last few years has been successful, with a reduction in remission rates of up to 80% for hematologic cancer, particularly for acute lymphoblastic leukemia (ALL) and non‑Hodgkin lymphomas, such as large B cell lymphoma. Recently, anti‑CD19 CAR therapy, or UCART19, has been shown to be efficacious in treating relapsed/refractory hematologic cancer. Several other cell surface tumor antigens, such as CD20 and CD22, found in the majority of leukemias and lymphomas are considered potential targets by pharmaceutical companies and research organizations, and trials have been ongoing in this direction. Although this therapeutic regimen is currently confined to treating hematologic cancer, the increasing involvement of several auxiliary techniques, such as bispecific CAR, Tan‑CAR, inhibitory‑CAR, combined antigens, the clustered regularly interspaced short palindromic repeats gene‑editing tool and nanoparticle delivery, may substantially improve its overall anticancer effects. CAR therapy has the potential to offer a rapid and safer treatment regime to treat non‑solid and solid tumors. The present review presents an insight into the advantages and the advances of CAR immunotherapy and presents the emerging discrepancy of CAR therapy over usual forms of therapy, such as chemotherapy and radiotherapy.
29 September 2025 in Proceedings of the National Academy of Sciences
The ideal delivery of therapeutic nanoparticles (NPs) to specific sites requires evading immune clearance and selectively binding target cells. Wrapping NPs in cell-derived membranes has shown promise in improving targeted delivery, but the mechanisms underlying this phenomenon are not fully understood. Protein corona (PC) formation on NPs can significantly alter their biological identity to influence biodistribution, making its characterization on membrane-wrapped NPs (MWNPs) and unwrapped NPs crucial. In this study, we compared MWNPs incorporating membranes derived from megakaryoblastic CHRF-288-11 cells, which can accumulate in bone marrow (BM) and preferentially bind hematopoietic stem and progenitor cells (HSPCs), with unwrapped NPs. We investigated differences in PC composition, macrophage uptake, target cell uptake, and biodistribution in wild type (WT) mice and knockout mice that have low or absent expression of different opsonin proteins. In vitro, MWNPs with a PC exhibited increased target cell uptake and decreased macrophage uptake compared to unwrapped NPs with a PC. Proteomics revealed apolipoprotein B as the dominant opsonin on both NP types after incubation in mouse, bovine, or human serum, with other proteins like complement, immunoglobulins, and apolipoproteins also being present. Biodistribution studies indicated a complex interplay between the PC and targeting/clearance, where complement component 3 and immunoglobulin G adsorption on MWNPs led to macrophage clearance but also enabled HSPC targeting. Meanwhile, apolipoprotein E adsorption facilitated hepatocyte clearance but reduced immune cell uptake in the liver. Future research on PCs could determine whether these mechanisms are generalizable to other types of MWNPs, potentially revealing strategies to enhance their effectiveness as delivery systems.
Chordomas account for approximately 1–4% of all malignant bone tumors and 20% of primary tumors of the spinal column. It is a rare disease, with an incidence estimated to be approximately 1 per 1,000,000 people. The underlying causative mechanism of chordoma is unknown, which makes it challenging to treat. Chordomas have been linked to the T-box transcription factor T (TBXT) gene located on chromosome 6. The TBXT gene encodes a protein transcription factor TBXT, or brachyury homolog. Currently, there is no approved targeted therapy for chordoma. Here, we performed a small molecule screening to identify small chemical molecules and therapeutic targets for treating chordoma. We screened 3730 unique compounds and selected 50 potential hits. The top three hits were Ribociclib, Ingenol-3-angelate, and Duvelisib. Among the top 10 hits, we found a novel class of small molecules, including proteasomal inhibitors, as promising molecules that reduce the proliferation of human chordoma cells. Furthermore, we discovered that proteasomal subunits PSMB5 and PSMB8 are increased in human chordoma cell lines U-CH1 and U-CH2, confirming that the proteasome may serve as a molecular target whose specific inhibition may lead to better therapeutic strategies for chordoma.
Intravenously delivered nanoparticle (NP) therapies have the potential to cure a variety of diseases; however, their clinical use has been stunted by undesirable levels of immune cell clearance. This clearance is attributed to protein adsorption onto the outside of the NPs, leading to recognition by immune cells and subsequent accumulation in the liver and spleen. Membrane-wrapped nanoparticles (MWNPs) offer a potential solution to reducing immune clearance by incorporating immune evasion/marker-of-self-proteins, although they too exhibit protein corona-mediated clearance. While various opsonin proteins can bind to MWNPs, complement proteins are particularly problematic as they play a crucial role in innate immunity, triggering immune cell recognition and clearance and causing inflammation. We hypothesized that introducing a complement regulatory protein into the membranes of MWNPs could minimize complement-mediated clearance, but the opposite effect was observed experimentally. In this study, before membrane collection, source cells were genetically modified to express the complement regulatory protein, CD55, which inhibits C3 convertases, key enzymes in the complement cascade. We confirmed that the active protein was transferred onto MWNPs and determined that CD55-modified MWNPs incubated in mouse serum significantly reduced C3 convertase concentration by 33% compared to unmodified MWNPs. Unexpectedly, in vivo analysis of biodistribution and immune cell uptake showed that CD55-modified MWNPs exhibited 2.1× higher spleen accumulation and elevated immune cell uptake in blood and spleen, specifically in monocyte/macrophage populations, as compared to unmodified MWNPs. This may be due to nonprotein corona-mediated mechanisms, such as the secondary role of CD55 as a ligand for CD97 (expressed in monocytes, macrophages, and other immune cells). Supporting this theory, studies examining ex vivo MWNP binding to spleen cells pretreated with IgG or CD97 antibodies showed that CD55-modified MWNPs had 18% lower binding after CD97 blockade, whereas unmodified MWNP binding was not reduced by CD97 blockade. These findings highlight the importance of considering both serum protein interactions and ligand/receptor interactions when designing genetically engineered MWNPs that overexpress a protein of interest, as well as the importance of testing modified MWNPs in both ex vivo and in vivo settings. In the future, the CD55 modification described here could be utilized to promote spleen tropism of MWNPs when desired. More broadly, this work demonstrates the ability to tune MWNP cellular interactions and biodistribution through genetic engineering of source cellsa technique that can be adapted for a plethora of uses in precision medicine.
Polymeric nanoparticle synthesis using lipophilic dye for tracking produces dye-only micelles which go undetected during characterization and cause false-positive signals. Density gradient centrifugation separates these micelles from nanoparticles. Created with BioRender.com.